Pain, Chest |
|
|
Clinical Trial: The Pain Pen for Breakthrough Cancer Pain
This study is currently recruiting patients.
Verified by Erasmus Medical Center August 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Neoplasms Pain | Drug: Subcutaneous hydromorphone delivered by pain pen | Phase III |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Pain
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Efficacy Study
Official Title: Breakthrough Cancer Pain: a Randomized Trial Comparing Oral Morphine Immediate Release and Self-Administration of Subcutaneous Hydromorphone Using an Injection Pen
Secondary Outcomes: PID 5''''; PID 10''''; PID 30''''; PID 45''''; PID 60''''; time to onset of meaningful pain relief; global efficacy rating at 60''''
Expected Total Enrollment: 50
Study start: August 2005; Expected completion: August 2007
Last follow-up: August 2005; Data entry closure: August 2007
Eligibility
Inclusion Criteria:
- stable cancer pain requiring the equivalent of 60-1000 mg oral morphine/day
- 1-4 breakthrough pain episodes/day
- patients must be able in the opinion of the investigator to fully comply with trial requirements
- patients who have given written informed consent
Exclusion Criteria:
- uncontrolled pain
- women who are pregnant, lactating or intend to become pregnant
- cardiopulmonary disease that would increase the risk of opioids
- neurologic or psychiatric disease that would compromise data collection
- recently started chemo or radiotherapy in as far as it would be effective in lowering breakthrough pain
Location and Contact Information
Netherlands
Dept. Neurology, Erasmus MC, Rotterdam, 3015 GD, Netherlands; Recruiting
Joost L. Jongen, MD, Principal Investigator
Joost L. Jongen, MD, Principal Investigator, Dept. Neurology, Erasmus MC
More Information
Publications
Enting RH, Mucchiano C, Oldenmenger WH, Fritzon M, Wallen A, Goslinga-van der Gaag S, Sillevis Smitt PA, Delhaas E. The "pain pen" for breakthrough cancer pain: a promising treatment. J Pain Symptom Manage. 2005 Feb;29(2):213-7.
Last Updated: August 1, 2005
Record first received: August 1, 2005
ClinicalTrials.gov Identifier: NCT00125801
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
ClinicalTrials.gov processed this record on 2005-08-02

Not Signed In -

